Announced Wed, 29 Apr · 18:28 IST

Inventurus Knowledge Solutions Limited has informed the Exchange about Transcript.

Analyst Day Multiyear TargetsCfo Debt Reduction RoadmapInvestor Communications View source PDF

IKS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+7.4%1-day move
₹1561.90
prior close
₹1561.90
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.9-0.8-0.1+0.5+7.4+7.5+6.8+8.6+7.9+6.5+1.0+5.0+7.6
Up moveDown movePending
AI summary

IKS Health announced the strategic acquisition of TruBridge, a US-based healthcare IT company listed on NASDAQ, for $557 million enterprise value ($427 million equity + $130 million debt). TruBridge operates in the rural hospital market with 700 hospitals under its EHR system and $347 million revenue (TTM 2025), split between $126M EHR and $221M RCM businesses. The combined entity will have ~$698 million revenue and ~$186 million adjusted EBITDA at close. The deal is immediately EPS accretive. Key strategic rationale includes creating an integrated system of record + system of action, building proprietary AI training corpus, and cross-selling RCM services (~$450 million white space) into TruBridge's captive install base. Management guided INR 3,000 crores EBITDA target by FY30, representing ~3x growth from current INR 1,000 crores EBITDA, with net debt expected to return to pre-deal levels by FY30.

Likely market impact

This acquisition provides IKS with a dominant system of record in the rural hospital niche ($164B market), creating a deep AI moat through integrated data. The deal is EPS accretive from day one but increases leverage to ~3x, which management expects to deleverage rapidly through synergies and growth. The 4-year EBITDA target implies strong confidence in cross-sell execution and cost synergies.